Exelixis Inc. | Ownership
Companies that own Exelixis Inc.
Fidelity Management & Research Co.
28,856,504
9.68%
-4,790,371
0.06%
06/30/2018
BlackRock Fund Advisors
26,623,444
8.93%
11,251,272
0.03%
06/30/2018
The Vanguard Group, Inc.
25,526,846
8.57%
-231,398
0.02%
06/30/2018
Meditor Capital Management Ltd.
15,966,038
5.36%
0
56.59%
06/30/2018
SSgA Funds Management, Inc.
10,603,584
3.56%
3,934,145
0.02%
06/30/2018
Matrix Capital Management Co. LP
10,000,000
3.36%
0
5.03%
06/30/2018
T. Rowe Price Associates, Inc.
4,833,478
1.62%
-5,265,367
0.01%
06/30/2018
Goldman Sachs & Co. LLC (Private Banking)
4,591,611
1.54%
-1,353,080
0.05%
06/30/2018
AQR Capital Management LLC
4,401,907
1.48%
-3,072,697
0.07%
06/30/2018
JPMorgan Investment Management, Inc.
4,050,207
1.36%
250,941
0.02%
06/30/2018
| Address |
1851 Harbor Bay
Parkway Alameda California 94502
United States
|
|
Employees
|
- |
| Website |
http://www.exelixis.com |
| Updated |
07/08/2019 |
| Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. |
